Fucoidan derived from Cladosiphon okamuranus Tokida ameliorates murine chronic colitis through the down-regulation of interleukin-6 production on colonic epithelial cells

Clinical and Experimental Immunology

Volumn 136, Issue 3, 2004, Pages 432-439

  Matsumoto, S ^a   Nagaoka, M ^a   Hara, T ^a   Kimura Takagi, I ^a   Mistuyama, K ^b   Ueyama, S ^a  

^a YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Experimental colitis; Fucoidan; IL 6; Inflammatory bowel disease intestinal epithelial cell; Ulcerative colitis

Indexed keywords

DEXTRAN; FUCOIDIN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; MYELOPEROXIDASE; SODIUM SULFATE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLADOSIPHON OKAMURANUS TOKIDA; COLITIS; COLON MUCOSA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DOWN REGULATION; ENZYME ACTIVITY; EPITHELIUM CELL; FEMALE; KJELLMANIELLA CRASSIFOLIA; LAMINA PROPRIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEAWEED;

ANIMALS; CHRONIC DISEASE; COLITIS; COLON; DEPRESSION, CHEMICAL; EPITHELIAL CELLS; FEMALE; FLOW CYTOMETRY; INTERLEUKIN-6; INTESTINAL MUCOSA; LYMPHOCYTES; MICE; MICE, INBRED BALB C; PHYTOTHERAPY; POLYSACCHARIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEAWEED;

EID: 2542551880     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02462.x     Document Type: Article

References (47)

1. Duchmann R, Kaiser I, Herhann E et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease. Clin Exp Immunol 1995; 102:448-55.
2. Duchmann R, May E, Heike M, Neurath M et al. T cell specifity and cross reactivity towards enterobacteria, Bacteroides, Bifidobacterium, and antigen from resident intestinal flora in humans. Gut 1999; 44:812-8.
3. Duchmann R, Schmitt E, Knolle P et al. Tolerance towards resident intestinal flora in mice is aborogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol 1996; 26:934-8.
4. Sadlack B, Merz H, Schorle H et al. Ulcerative colitis-like disease in mice with disrupted interleukin-2 gene. Cell 1993; 75:253-61.
5. Taurog JD, Richardson JA, Croft JT et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180:2359-64.
6. Matsumoto S, Okabe Y, Setoyama H et al. Inflammatory bowel disease-like enteritis and caecitis in a senescence accelerated mouse P1/Yit strain. Gut 1998; 43:71-8.
7. + cells in the exacerbation of inflammatory bowel disease in TCRα mutant mice. Eur J Immunol 2001; 31:980-8.
8. Podolsky DK. Inflammatory bowel disease. N Engl J Med 1991; 325:928-37.
9. Gross V, Andus T, Caesar I et al. Evidence for continuous stimulation of IL-6 production in Crohn's disease. Gastroenterology 1992; 102:514-9.
10. + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. J Immunol 1996; 157:1261-70.
11. Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J Surg 1998; 22:382-9.
12. Yamamoto M, Yoshizaki K, Kishimoto T, Ito H. IL-6 is required for the development of Th-1 cell mediated murine colitis. J Immunol 2000; 164:4878-82.
13. Atreya R, Mudter J, Finotto S et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn's disease and experimental colitis in vivo. Nat Med 2000; 6:583-8.
14. Ohshima S, Saeki Y, Mima T et al. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci USA 1998; 95:8222-6.
15. Alonzi T, Fattori E, Lazzaro D et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 1998; 187:461-8.
16. Suzuki A, Hanada T, Mitsuyama K et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 2001; 193:471-81.
17. O'Farrell AM, Liu Y, Moore KW, Mui AL. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways. EMBO J 1998; 17:1006-18.
18. Yasukawa H, Sasaki A, Yoshimura A. Negative regulation of cytokine signaling pathways. Annu Rev Immunol 2000; 18:143-64.
19. Hungness ES, Pritts TA, Luo GJ et al. The transcription factor activator protein-1 is activated and interleukin-6 production is increased in interleukin-1beta-stimulated human enterocytes. Shock 2000; 14:386-91.
20. Morrison DC, Ryan JL. Bacterial endotoxins and host immune responses. Adv Immunol 1979; 28:293-450.
21. Ulevitch RJ, Tobias PS. Receptor-dependent mechanisms of by bacterial endotoxin. Annu Rev Immunol 1995; 13:437-57.
22. Skidmore BJ, Morrison DC, Chiller JM, Weigle WO. Immunologic properties of bacteroides lipopolysaccharide (LPS). The unresponsiveness of C3H/HeJ mouse spleen cells to LPS-iriduced mitogenesis is dependent on the method used to extract LPS. J Exp Med 1975; 142:1488-504.
23. Keighley MR, Arabi Y, Dimock F et al. Influence of inflammatory bowel disease on intestinal microflora. Gut 1978; 19:1099-104.
24. Rath HC, Ikeda JS, Linde HJ et al. Varying cecal bacterial loads influences colitis and gastritis in HLA-B27 transgenic rats. Gastroenterology 1999; 116:310-9.
25. Lange S, Delbro DS, Jennische E, Mattsby-Baltzer I. The role of the Lps gene in experimental ulcerative colitis in mice. APMIS 1996; 104:823-33.
26. Cario E, Rosenberg IM, Brandwein SL et al. Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing toll-like receptors. J Immunol 2000; 164:966-72.
27. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR-3) and TLR-4 in inflammatory bowel disease. Infect Immun 2000; 68:7010-7.
28. Mahony MC, Oehninger S, Clark GF, Acosta AA. Fucoidan inhibits the zona pellucida-induced acrosome reaction in human spermatozoa. Contraception 1991; 44:657-65.
29. Baba M, Snoeck R, Pauwels R, DeClerq E. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob Agents Chemother 1994; 32:1742-5.
30. Shibata H, Kimura-Takagi I, Nagaoka M et al. Inhibitory effect of Cladosiphon fucoidan on the adhesion of Helicobactor pylori to human gastric cells. J Nutr Sci Vitaminol 1999; 45:325-36.
31. Nagaoka M, Shibata H, Kimura-Takagi I et al. Structural study of fucoidan from Cladosiphon okamuranus Tokida. Glycoconj J 1999; 16:19-26.
32. Okuyasu I, Hatakeyama S, Yamada M et al. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990; 98:694-702.
33. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993; 69:238-49.
34. Matsumoto S, Watanabe N, Umesaki Y. Roles of chloroform-resistant variants in mouse models of experimental colitis. Microb Ecol Health Dis 2000; 12:102-8.
35. Matsumoto S, Nonno M, Watanabe N, Miyashita M et al. Physiological roles of γδT-cell receptor intraepithelial lymphocytes in cytoproliferation and differentiation of mouse intestinal epithelial cells. Immunology 1999; 97:18-25.
36. Kikuchi T, Matsuguchi T, Tsuboi N et al. Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoclasts via toll-like receptors. J Immunol 2001; 166:3574-9.
37. Krawisz JE, Sharon P, Stenson F. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Gastroenterology 1984; 87:1344-50.
38. Matsumoto S, Watanabe N, Imaoka A, Okabe Y. Preventive effects of Bifidobacterium- and Lactobacillus-fermented milk on the development of inflammatory bowel disease in senescence-accelerated mouse (SAM) P1/Yit strain mice. Digestion 2001; 64:92-9.
39. Hirano T, Akira S, Taga T, Kishimoto T. Biological and clinical aspects of interleukin 6. Immunol Today 1990; 12:443-9.
40. Hosokawa T, Kushigami K, Ando T et al. Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease. J Gastroenterol Hepatol 1999; 14:987-96.
41. Sitaraman SV, Merlin D, Wang L et al. Neutrophil-epithelial crosstalk at the intestinal luminal surface mediated by reciprocal secretion of adenosine and IL-6. J Clin Invest 2001; 107:861-9.
42. + T cells. Immunity 1994; 1:553-62.
43. Neurath MF, Kelsall BL, Presky DH et al. Experimental granulomatous colitis in mice is abrogated by induction of TGF-β-mediated oral tolerance. J Exp Med 1996; 183:2605-16.
44. Hagenbaugh A, Sharma S, Dubinett SM et al. Altered immune responses in interleukin 10 transgenic mice. J Exp Med 1997; 185:2101-10.
45. Nomura F, Araki S, Sakao Y et al. Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with downregulation of surface toll-like receptor 4 expression. J Immunol 2000; 164:3476-9.
46. Zhang XZ, Liu Q, Thorlacius H. Inhibition of selectin function and leukocyte rolling protects against dextran sodium sulfate-induced colitis. Scand J Gastroenterol 2001; 36:270-5.
47. Swidsinski A, Ladhoff A, Pernthaler A et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122:44-54.